

HALOGEN-CONTAINING CHALCONES AS VERSATILE BIOACTIVE AGENTS: A REVIEW

Konul Shahverdiyeva, Samira Ismayilova, Alakbar Huseynzada, Ulviyya Hasanova, Niftali Yusubov, Valeh Ismayilov
Baku State University, Baku, Azerbaijan

*Received: 29 august 2025
Accepted: 30 october 2025
Published: 31 october 2025*

Along with the increase in the world population, the number and types of various diseases are also showing an increasing trend. This creates an important need to design and test a large number of drug molecules for the treatment of diseases. Throughout history, compounds existing in nature have been widely used for the treatment of diseases. Chalcones are widely distributed in nature in various plants and have been intensively used in medicine due to their biological activities, such as antibacterial, anti-inflammatory, and antioxidant. Despite the simplicity of the structure of these molecules and the ease of the synthesis process, their biological activities are significantly broad. Thus, as a result of the development of synthesis methods and biological studies, the structure of chalcones distributed in nature has been studied in depth, new chalcone derivatives have been synthesised based on these structures, and as a result of biological studies, it has been found that new chalcone derivatives, especially halogen-bearing chalcone molecules, exhibit a wide spectrum of biological activity. According to the results of recent studies, bromine and chlorine-containing chalcone molecules exhibit better anticancer, antifungal, and antibacterial activity compared to existing antibiotics and drugs. This article is devoted to a review of recent scientific research works on the synthesis and biological studies of new derivatives of chalcones, mainly halogen derivatives.

Keywords: halogen derivatives of chalcones; bioactivity; structure-activity relationship

INTRODUCTION

Microorganisms are developing resistance to conventional antimicrobial agents available in clinical practice, and there is a need to search for more active, effective, less toxic and cost-effective alternatives to existing drugs. Many studies have been conducted to investigate the therapeutic properties of chalcones and their various derivatives [1-3]. Chalcones, which are secondary metabolites of edible or medicinal plants, are included in the flavonoid family. Chalcones, which are 1,3-diphenyl-2-propen-1-ones, are based on two aryl moieties linked through an α,β -unsaturated carbonyl group [4]. These compounds are mainly polyphenolic compounds that range in colour from yellow to orange and contribute significantly to the pigmentation of the crown of some plants. Chalcones, which are naturally found in fruits, spices, teas and soy-based foods, have attracted much attention due to their potentially beneficial properties.




Figure 1. Naturally occurring chalcones

In addition, these molecules are present in natural products as pheromones, plant allelochemicals and insect hormones [5,6]. Chalcones can participate in many chemical reactions and are also used to synthesize heterocyclic compounds. A wide variety of chalcone derivatives can be synthesized by reacting aromatic aldehydes with aryl ketones in the presence of appropriate amounts of condensing agents [7]. A significant portion of medicinal chemistry research in the 21st century has focused on both natural and synthetic chalcones, as they possess diverse pharmacological potential, including antibacterial, [8,10] anti-inflammatory, [11-13] analgesic, [14,15] anticholinergic, [16] antiplatelet, [17] antiulcer, [18] antioxidant, [19,20] antimalarial, [21] anticancer, [22,23] antiviral, [24,27] anti-leishmanial, [28] antidiabetic, [29,30] immunomodulatory, [31,32] aldose reductase inhibition, [33] estrogenic, [34]. Chalcones are highly attractive molecules due to their simple structure, ease of synthesis, and promising biological applications. Several modifications of the chromophore of chalcones have been reported, including hydroxyl, methoxy, and amino groups as substituents with promising anticancer and antimicrobial activities [35-37]. The introduction of a chlorine atom into the chalcone structure can enhance its bioactivity, including antibacterial properties [38-40]. When a chlorine atom is introduced into the B ring of 2'-hydroxychalcone, it enhances its antituberculosis activity against *Mycobacterium tuberculosis* H37Rv strain [40]. In view of the above, this review aims to provide a comprehensive overview of recent research efforts devoted to the synthesis and biological activity of halogen-bearing chalcones, highlighting their potential as versatile compounds for the development of novel bioactive agents.

RESULTS AND DISCUSSION

Chalcones are compounds containing an α,β -unsaturated ketone system, which causes them to behave as pharmacophore compounds and exhibit a number of biological activities such as anticancer, anti-inflammatory, antiviral, antibacterial, antifungal, etc.[41]

The addition of various groups to the structure of chalcones also affects their bioactivity. A number of groups, especially halogen functional groups, regulate the electron distribution throughout the molecule, increasing membrane permeability and making the binding to biological targets more effective. Due to their large size and electronegativity, Cl and Br atoms help to bind to the active centers through halogen bonds and hydrophobic interactions. Changes in the inhibitory activity of the substance can also be observed depending on the position of the halogen on the ring. It is noticeable in literature that more para-substituted derivatives show higher effects. [42]

New halogenated chalcone derivatives were introduced by Chlupacova et al. The synthesized bioactive substances, which contain electron-withdrawing groups in the aromatic ring, have a number of inhibitory properties. Chalcone 1 (Figure 2) showed a positive effect on ciprofloxacin by inhibiting *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli*, *Salmonella typhimurium*, and *Klebsiella aerogenes*.

In case of the comparison with its corresponding flavone, the antifungal properties of the chalcone 2 (Figure 3) showed more satisfactory results against *Trichophyton longifusus*, *Microsporum canis*, and *Aspergillus flavus* than the corresponding flavone.

Compound 3 (Figure 4) surpassed ketoconazole in its antifungal activity against dermatophytes with a minimum inhibitory concentration of 0.5-25 µg/mL. [43]




Figure 2. Chalcone 1




Figure 3. Chalcone 2




Figure 4. Chalcone 3

Bis(chalcone) derivatives were prepared by Burmaoglu and his group from the reaction of 1,1-(2-hydroxy-4,6-dimethoxy-1,3-phenylene)bis (ethan-1-one) (2) with benzaldehydes. The general structure of the reactions obtained with the participation of an aqueous solution of potassium hydroxide. The cytotoxicity of these novel compounds was tested utilization of MTT analysis of pulmonary carcinoma. IC₅₀ analysis indicated that the bis(chalcone) derivative (Figure 5) had a marked cytotoxic effect on A-549 and Caco-2 cancer cell lines. [44]




Figure 5. Bis(chalcone) derivative

Flavone compound (Figure 7) was synthesized from brominated chalcone (Figure 6) in the presence of NaOH. The compound showed pronounced cytotoxic activity against A-549 and Caco-2 cancer cell lines. Flow cytometry analysis showed that it induced cell cycle arrest mainly in S and G₂/M phases. Western blot results supported these findings and showed increased expression of p53 and p27 proteins. Furthermore, fluorescence microscopy confirmed that compound 6 induced apoptosis in a concentration-dependent manner, indicating its potential as a promising anticancer agent. [45]




Figure 6. Brominated chalcone derivative




Figure 7. Brominated flavone derivative

Chalcone derivatives prepared in the presence of 4-hydroxyacetophenone and halogenated benzaldehydes and their Mannich bases are substances with protective activity containing halogen groups in their structures, as presented by Yamali and his group. Cellular toxicity of chalcones was evaluated against oral cells and cell lines. The number of cells were examined by MTT method. Among these substances, 3-(4-bromophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (Figure 8) was investigated for its cytotoxicity potential and selective toxicity, and PSE values were measured. The studies conducted showed that chalcone has a satisfactory effect against oral cancer cells (HCS-2, HCS-3, and HCS-4) with a CC₅₀ of 5.7 µM, while its toxic effect against normal cells is quite low at 40 µM. [46]




Figure 8. 3-(4-bromophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one

2-aminopyrimidine derivatives and homocyclic pyrimidine derivatives (Figure 9) were prepared in a two-step process. Compounds 9 were initially obtained by condensation of chalcone precursors with guanidine nitrate in ethanolic NaOH. Compounds 10 were obtained in 75–85% yield by reacting the resulting amino-substituted pyrimidines with 4-chloro-2,6-dimethylquinoline in the presence of anhydrous potassium carbonate and tetrahydrofuran. The halogen (Cl, Br, and F) and methoxy groups in the aromatic ring, which enhance their interaction with biological targets and overall efficacy, primarily contribute to the significant antibacterial activity of both pyrimidines.[47]




Figure 9. Synthesis procedure of 2-aminopyrimidine derivatives and homocyclic pyrimidine derivatives

A series of 2-hydroxy-3-nitrochalcones substituted with 5-methyl, 5-bromo, and 5-chloro were prepared. The compounds were then evaluated for their ability to inhibit α -glucosidase and α -amylase activity in vitro using enzymatic assays. Compared with the antidiabetic drug acarbose, most of the tested compounds showed greater inhibitory potency against α -glucosidase. Compared with the anticancer drug curcumin, chalcones showed a dual inhibitory effect on both enzymes without cytotoxicity against Raw-264.7 macrophage cells (mouse). [48]

Sun and colleagues conducted antiviral studies on a novel chalcone derivative. New compound (Figure 10), a chalcone derivative bearing an oxygen bridge and a 4-bromophenyl substituent at position 5, exhibited moderate antiviral activity against tobacco mosaic virus (TMV) in vivo. Its viral inactivation rate ($63.1 \pm 7.6\%$) was higher than its therapeutic ($37.4 \pm 4.6\%$) and protective ($42.9 \pm 7.7\%$) effects. This suggests that it focuses on direct virus inactivation.[49]




Figure 10. 4-bromophenyl substituted novel chalcone

Chen et al. synthesized pyridazine-based halogenated chalcones. (Figure 11) The antibacterial properties of these chalcones were tested against *Xanthomonas axonopodis* pv. citri (Xac), *Pseudomonas syringae* pv. actinidiae (Psa), and *Xanthomonas oryzae* pv. oryzae (Xoo). The compounds at concentrations of 50 and 100 $\mu\text{g}/\text{mL}$ showed different effects against

the bacteria. Compound C showed high and significant effects against Xac and Xoo, respectively, at 100 µg/mL. B' showed a stable inhibition pattern against all tested pathogens, with $29.72 \pm 6.62\%$ for Xac, $14.77 \pm 0.89\%$ for Psa, and $35.66 \pm 1.31\%$ for Xoo at 100 µg/mL. A' showed moderate effects compared to the others, while compounds A and B showed weak but significant effects.[50]





Figure 11. Pyridazine-based halogenated chalcones

To evaluate the potential of the biological activity of synthesized halogenated derivatives of trimethoxychalcone (Figure 12), their inhibitory effect on key enzymes, such as MAO-A, MAO-B, AChE, BChE, and BACE-1, was studied by Vishal and his group. Compounds A and B showed the strongest inhibitory activity against MAO-A and MAO-B enzymes. Both derivatives showed good selectivity over MAO-B, with SI values of 15.1 and 31.1, respectively, which means that they performed better than the reference inhibitor Toloxatone. In addition, both showed moderate activity against AChE and BChE enzymes, while compound A was significantly more effective against BACE-1. The results obtained make these novel chalcone derivatives suitable for the design of neurotherapeutic multifunctional reagents.[51]



- A. R1=OCH3, R2=OCH3, R3=OCH3, R4=H, X=Cl
B. R1=OCH3, R2=OCH3, R3=OCH3, R4=H, X=Br
C. R1=OCH3, R2=OCH3, R3=OCH3, R4=H, X=I

Figure 12. Halogenated derivatives of trimethoxychalcone

Novel 2-arylidene-3, 4-dihydronaphthalen-1(2H)-one derivatives (Figure 13) of chalcones were generated by Gupta et al., and their antifungal properties were investigated against *C. albicans*, *A. niger*, and *M. gypseum*. Chlorinated compound exhibited remarkable antifungal activity against *M. gypseum* with better inhibitor activity than ketoconazole. The brominated derivative of the significant chalcone showed average activity in comparison to the chlorinated one.[52]




Figure 13. Novel 2-arylidene-3, 4-dihydronaphthalen-1(2H)-one derivatives

Antifungal activity of twenty chalcone derivatives (Figure 14) was obtained by Zhou and his team, investigated against several fungal species at 100 mg/ L using the mycelial growth rate method. The results were compared to the agricultural fungicide azoxystrobin. *Fusarium oxysporum* f. sp. *cucumerinum*, *Colletotrichum capsici*, *Botrytis cinerea*, *Phytophthora parasitica*, *Fusarium moniliforme*, *R. solani*, *Alternaria brassicae*, *Colletotrichum gloeosporioides*, *Peronophythora litchii*, and *Fusarium graminearum* were chosen as target yeasts. [53]




Figure 14. Synthesis procedure of 20 antifungal chalcone derivatives

According to the general results, the D2 compound has very high inhibition percentages against the most molds, especially *R. solani* and *A. brassicae*. EC₅₀ values for this chalcone derivative change between 0.3 and 38.5 mg/L, which corresponds to the best antifungal activity against the given species among 20 compounds. Additionally, D16 compound exhibited an overall strong impact against fungal pathogens. The inhibition percentage of D20 compound against *R. solani* was evaluated as 73.8, and against *A. brassicae* was 30.4.

CONCLUSION

The chemically facile synthesis and modification of chalcones is very convenient for the development of drug candidates with diverse functionalities. This review summarizes the synthesis and biological activity of halogen-bearing chalcone derivatives. The review shows the effect of the addition of halogen atoms, especially chlorine and bromine, to the chalcone molecule, as well as the location of the halogen atom in the molecule on the structure-activity

relationship, as well as the role of these properties in biological activity and their effectiveness compared to existing drugs. The listed data will make a significant contribution to the synthesis of new chalcone derivatives and the study of their biological properties.

REFERENCES

- [1] Nielsen, S. F., Christensen, S. B., Cruciani, G., Kharazmi, A., & Liljefors, T. (1998). Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. *Journal of Medicinal Chemistry*, 41(24), 4819-4832. <https://doi.org/10.1021/jm980410m>
- [2] Park, E. J., Park, H. R., Lee, J. S., & Kim, J. (1998). Licochalcone A: an inducer of cell differentiation and cytotoxic agent from *Pogostemon cabling*1. *Planta medica*, 64(05), 464-466. <https://doi.org/10.1055/s-2006-957485>
- [3] Ko, H. H., Tsao, L. T., Yu, K. L., Liu, C. T., Wang, J. P., & Lin, C. N. (2003). Structure-activity relationship studies on chalcone derivatives: the potent inhibition of chemical mediators release. *Bioorganic & medicinal chemistry*, 11(1), 105-111. [https://doi.org/10.1016/S0968-0896\(02\)00312-7](https://doi.org/10.1016/S0968-0896(02)00312-7)
- [4] Alam, M. S., Rahman, S. M., & Lee, D. U. (2015). Synthesis, biological evaluation, quantitative-SAR and docking studies of novel chalcone derivatives as antibacterial and antioxidant agents. *Chemical Papers*, 69(8), 1118-1129. <https://doi.org/10.1515/chempap-2015-0113>
- [5] Wadleigh, R. W., & Simon, J. Y. (1987). Glutathione transferase activity of fall armyworm larvae toward α , β -unsaturated carbonyl allelochemicals and its induction by allelochemicals. *Insect Biochemistry*, 17(5), 759-764. [https://doi.org/10.1016/0020-1790\(87\)90046-1](https://doi.org/10.1016/0020-1790(87)90046-1)
- [6] Karthikeyan, C., SH Narayana Moorthy, N., Ramasamy, S., Vanam, U., Manivannan, E., Karunagaran, D., & Trivedi, P. (2015). Advances in chalcones with anticancer activities. Recent patents on anti-cancer drug discovery, 10(1), 97-115. <https://doi.org/10.2174/1574892809666140819153902>
- [7] Kumar, S., Nepali, K., Sapra, S., Suri, O. P., Dhar, K. L., Sarma, G. S., & Saxena, A. K. (2010). Synthesis and biological evaluation of chalcones having heterosubstituent (s). *Indian journal of pharmaceutical sciences*, 72(6), 801. <https://doi.org/10.4103/0250-474X.84602>
- [8] Okolo, E. N., Ugwu, D. I., Ezema, B. E., Ndefo, J. C., Eze, F. U., Ezema, C. G., ... & Ujam, O. T. (2021). New chalcone derivatives as potential antimicrobial and antioxidant agent. *Scientific reports*, 11(1), 21781. <https://doi.org/10.1038/s41598-021-01292-5>
- [9] Benouda, H., Bouchal, B., Challioui, A., Oulmidi, A., Harit, T., Malek, F., ... & Bouammali, B. (2019). Synthesis of a series of chalcones and related flavones and evaluation of their antibacterial and antifungal activities. *Letters in Drug Design & Discovery*, 16(1), 93-100. <https://doi.org/10.2174/1570180815666180404130430>
- [10] Henry, E. J., Bird, S. J., Gowland, P., Collins, M., & Cassella, J. P. (2020). Ferrocenyl chalcone derivatives as possible antimicrobial agents. *The Journal of antibiotics*, 73(5), 299-308. <https://doi.org/10.1038/s41429-020-0280-y>
- [11] Nurkenov, O. A., Ibraev, M. K., Schepetkin, I. A., Khlebnikov, A. I., Seilkhanov, T. M., Arinova, A. E., & Isabaeva, M. B. (2019). Synthesis, structure, and anti-inflammatory activity of functionally substituted chalcones and their derivatives. *Russian Journal of General Chemistry*, 89(7), 1360-1367. <https://doi.org/10.1134/s1070363219070028>
- [12] Rashid, H., Xu, Y., Ahmad, N., Muhammad, Y., & Wang, L. (2019). Promising anti-inflammatory effects of chalcones via inhibition of cyclooxygenase, prostaglandin E2, inducible NO synthase and nuclear factor kb activities. *Bioorganic Chemistry*, 87, 335-365. <https://doi.org/10.1016/j.bioorg.2019.03.033>
- [13] Ibrahim, T. S., Moustafa, A. H., Almaki, A. J., Allam, R. M., Althagafi, A., Md, S., & Mohamed, M. F. (2021). Novel chalcone/aryl carboximidamide hybrids as potent anti-inflammatory via inhibition of prostaglandin E2 and inducible NO synthase activities: design, synthesis, molecular docking studies and ADMET prediction. *Journal of enzyme*

- inhibition and medicinal chemistry, 36(1), 1067-1078.
<https://doi.org/10.1080/14756366.2021.1929201>
- [14] Higgs, J., Wasowski, C., Marcos, A., Jukič, M., Pavan, C. H., Gobec, S., ... & Marder, M. (2019). Chalcone derivatives: synthesis, in vitro and in vivo evaluation of their anti-anxiety, anti-depression and analgesic effects. *Heliyon*, 5(3).
<https://doi.org/10.1016/j.heliyon.2019.e01376>
- [15] Lakshminarayanan, B., Kannappan, N., & Subburaju, T. (2020). Synthesis and biological evaluation of novel chalcones with methanesulfonyl end as potent analgesic and anti-inflammatory agents. *Int. J. Pharm. Res. Biosci*, 11(10), 4974-4981.
<https://doi.org/10.9734/bpi/acpr/v7/11562f>
- [16] Murtaza, S., Mir, K. Z., Tatheer, A., & Ullah, R. S. (2019). Synthesis and evaluation of chalcone and its derivatives as potential anticholinergic agents. *Letters in Drug Design & Discovery*, 16(3), 322-332. <https://doi.org/10.2174/1570180815666180523085436>
- [17] Fakhruddin, N., Pertiwi, K. K., Takubessi, M. I., Susiani, E. F., Nurrochmad, A., Widyarini, S., ... & Wahyuono, S. (2020). A geranylated chalcone with antiplatelet activity from the leaves of breadfruit (*Artocarpus altilis*). *Pharmacia*, 67(4), 173-180.
<https://doi.org/10.3897/pharmacia.67.e56788.figure4>
- [18] N Choudhary, A., Kumar, A., & Juyal, V. (2012). Design, synthesis and evaluation of chalcone derivatives as anti-inflammatory, antioxidant and antiulcer agents. *Letters in Drug Design & Discovery*, 9(5), 479-488. <https://doi.org/10.2174/157018012800389368>
- [19] Al Zahrani, N. A., El-Shishtawy, R. M., Elaasser, M. M., & Asiri, A. M. (2020). Synthesis of novel chalcone-based phenothiazine derivatives as antioxidant and anticancer agents. *Molecules*, 25(19), 4566. <https://doi.org/10.3390/molecules25194566>
- [20] Bale, A. T., Salar, U., Khan, K. M., Chigurupati, S., Fasina, T., Ali, F., ... & Perveen, S. (2021). Chalcones and bis-chalcones analogs as DPPH and ABTS radical scavengers. *Letters in Drug Design & Discovery*, 18(3), 249-257.
<https://doi.org/10.2174/1570180817999201001155032>
- [21] Qin, H. L., Zhang, Z. W., Lekkala, R., Alsulami, H., & Rakesh, K. P. (2020). Chalcone hybrids as privileged scaffolds in antimalarial drug discovery: A key review. *European journal of medicinal chemistry*, 193, 112215. <https://doi.org/10.1016/j.ejmech.2020.112215>
- [22] Čižmaríková, M., Takáč, P., Spengler, G., Kincses, A., Nové, M., Vílková, M., & Mojžiš, J. (2019). New chalcone derivative inhibits ABCB1 in multidrug resistant T-cell lymphoma and colon adenocarcinoma cells. *Anticancer Research*, 39(12), 6499-6505.
<https://doi.org/10.21873/anticanres.13864>
- [23] Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., & Wu, Q. (2021). Chalcone derivatives: role in anticancer therapy. *Biomolecules*, 11(6), 894. <https://doi.org/10.3390/biom11060894>
- [24] Duran, N., Polat, M. F., Aktas, D. A., Alagoz, M. A., Ay, E., Cimen, F., ... & Algul, O. (2021). New chalcone derivatives as effective against SARS-CoV-2 agent. *International Journal of Clinical Practice*, 75(12), e14846. <https://doi.org/10.1111/ijcp.14846>
- [25] Fu, Y., Liu, D., Zeng, H., Ren, X., Song, B., Hu, D., & Gan, X. (2020). New chalcone derivatives: synthesis, antiviral activity and mechanism of action. *RSC advances*, 10(41), 24483-24490. <https://doi.org/10.1039/d0ra03684f>
- [26] Kalirajan, R. (2020). Activity of some novel chalcone substituted 9-anilinoacridines against coronavirus (COVID-19): a computational approach. *Coronaviruses*, 1(1), 13-22.
<https://doi.org/10.2174/2666796701999200625210746>
- [27] Alsafi, M. A., Hughes, D. L., & Said, M. A. (2020). First COVID-19 molecular docking with a chalcone-based compound: synthesis, single-crystal structure and Hirshfeld surface analysis study. *Crystal Structure Communications*, 76(12), 1043-1050.
<https://doi.org/10.1107/s2053229620014217>
- [28] Escrivani, D. O., Charlton, R. L., Caruso, M. B., Burle-Caldas, G. A., Borsodi, M. P. G., Zingali, R. B., ... & Steel, P. G. (2021). Chalcones identify cTXNPx as a potential antileishmanial drug target. *PLoS neglected tropical diseases*, 15(11), e0009951.
<https://doi.org/10.1371/journal.pntd.0009951>

- [29] Jain, A., & Jain, D. (2019). Synthesis, characterization and biological evaluation of some new heterocyclic derivatives of chalcone as antihyperglycemic agents. *Int. J. Pharmaceutical Sci. Res*, 59, 5700-5706. <https://doi.org/10.9734/jpri/2022/v34i15b35716>
- [30] Welday Kahssay, S., Hailu, G. S., & Taye Desta, K. (2021). Design, synthesis, characterization and in vivo antidiabetic activity evaluation of some chalcone derivatives. *Drug Design, Development and Therapy*, 3119-3129. <https://doi.org/10.2147/dddt.s316185>
- [31] Lee, J. S., Bukhari, S. N. A., & Fauzi, N. M. (2015). Effects of chalcone derivatives on players of the immune system. *Drug design, development and therapy*, 4761-4778. <https://doi.org/10.2147/dddt.s86242>
- [32] Bhoj, P., Togle, N., Bahekar, S., Goswami, K., Chandak, H., & Patil, M. (2019). Immunomodulatory activity of sulfonamide Chalcone compounds in mice infected with filarial parasite, *Brugia malayi*. *Indian Journal of Clinical Biochemistry*, 34(2), 225-229. <https://doi.org/10.1007/s12291-017-0727-5>
- [33] Reddy, M. R., Aidhen, I. S., Reddy, U. A., Reddy, G. B., Ingle, K., & Mukhopadhyay, S. (2019). Synthesis of 4-C- β -D-Glucosylated Isoliquiritigenin and Analogues for Aldose Reductase Inhibition Studies. *European Journal of Organic Chemistry*, 2019(24), 3937-3948. <https://doi.org/10.1002/ejoc.201900413>
- [34] Shah, U., Patel, S., Patel, M., Gandhi, K., & Patel, A. (2020). Identification of chalcone derivatives as putative non-steroidal aromatase inhibitors potentially useful against breast cancer by molecular docking and ADME prediction. *Indian Journal of Chemistry-Section B (IJC-B)*, 59(2), 283-293. <https://doi.org/10.56042/ijcb.v59i2.27865>
- [35] Cabrera, M., Simoens, M., Falchi, G., Lavaggi, M. L., Piro, O. E., Castellano, E. E., ... & González, M. (2007). Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure–activity relationships. *Bioorganic & Medicinal Chemistry*, 15(10), 3356-3367. <https://doi.org/10.1016/j.bmc.2007.03.031>
- [36] Xia, Y., Yang, Z. Y., Xia, P., Bastow, K. F., Nakanishi, Y., & Lee, K. H. (2000). Antitumor agents. Part 202: novel 2'-amino chalcones: design, synthesis and biological evaluation. *Bioorganic & medicinal chemistry letters*, 10(8), 699-701. [https://doi.org/10.1016/S0960-894X\(00\)00072-X](https://doi.org/10.1016/S0960-894X(00)00072-X)
- [37] Ducki, S., Rennison, D., Woo, M., Kendall, A., Chabert, J. F. D., McGown, A. T., & Lawrence, N. J. (2009). Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivasular activity. *Bioorganic & medicinal chemistry*, 17(22), 7698-7710. <https://doi.org/10.1016/j.bmc.2009.09.039>
- [38] Konečná, K., Diepoltová, A., Holmanová, P., Jand'ourek, O., Vejsová, M., Voxová, B., ... & Kučerová-Chlupáčová, M. (2022). Comprehensive insight into anti-staphylococcal and anti-enterococcal action of brominated and chlorinated pyrazine-based chalcones. *Frontiers in Microbiology*, 13, 912467. <https://doi.org/10.3389/fmicb.2022.912467>
- [39] Prasad, Y. R., Rao, A. L., & Rambabu, R. (2008). Synthesis and antimicrobial activity of some chalcone derivatives. *Journal of Chemistry*, 5(3), 461-466. <https://doi.org/10.1155/2008/876257>
- [40] Lin, Y. M., Zhou, Y., Flavin, M. T., Zhou, L. M., Nie, W., & Chen, F. C. (2002). Chalcones and flavonoids as anti-tuberculosis agents. *Bioorganic & medicinal chemistry*, 10(8), 2795-2802. [https://doi.org/10.1016/S0968-0896\(02\)00094-9](https://doi.org/10.1016/S0968-0896(02)00094-9)
- [41] Jasim, H. A., Nahar, L., Jasim, M. A., Moore, S. A., Ritchie, K. J., & Sarker, S. D. (2021). Chalcones: Synthetic chemistry follows where nature leads. *Biomolecules*, 11(8), 1203. <https://doi.org/10.3390/biom11081203>
- [42] Avila-Sorrosa, A., Laurel-Gochicoa, D. J., Vargas-Díaz, M. E., Noguera-Torres, B., & Gómez-Escobedo, R. I. (2024). Easy synthesis and in vitro evaluation of halogenated Chalcones against *Trypanosoma cruzi*. *Chemistry*, 6(5), 1201-1216. <https://doi.org/10.3390/chemistry6050069>
- [43] Kucerova-Chlupacova, M., Vyskovska-Tyllova, V., Richterova-Finkova, L., Kunes, J., Buchta, V., Vejsova, M., ... & Opletalova, V. (2016). Novel halogenated pyrazine-based chalcones as potential antimicrobial drugs. *Molecules*, 21(11), 1421. <https://doi.org/10.3390/molecules21111421>

- [44] Burmaoglu, S., Gobek, A., Aydin, B. O., Yurtoglu, E., Aydin, B. N., Ozkat, G. Y., ... & Algul, O. (2021). Design, synthesis and biological evaluation of novel bischalcone derivatives as potential anticancer agents. *Bioorganic chemistry*, 111, 104882. <https://doi.org/10.1016/j.bioorg.2021.104882>
- [45] Dias, T. A., Duarte, C. L., Lima, C. F., Proenca, M. F., & Pereira-Wilson, C. (2013). Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin. *European Journal of Medicinal Chemistry*, 65, 500-510. <https://doi.org/10.1016/j.ejmech.2013.04.064>
- [46] Yamali, C., Gul, H. I., Sakagami, H., & Supuran, C. T. (2016). Synthesis and bioactivities of halogen bearing phenolic chalcones and their corresponding bis Mannich bases. *Journal of enzyme inhibition and medicinal chemistry*, 31(sup4), 125-131. <https://doi.org/10.1080/14756366.2016.1221825>
- [47] Farooq, S., & Ngaini, Z. (2021). One-pot and two-pot methods for chalcone derived pyrimidines synthesis and applications. *Journal of Heterocyclic Chemistry*, 58(6), 1209-1224. <https://doi.org/10.1002/jhet.4226>
- [48] Mphahlele, M. J., Maluleka, M. M., Choong, Y. S., Monchusi, B. A., & Mbazima, V. G. (2022). An in vitro study of the 5-methyl-and 5-bromo/chloro substituted 2-hydroxy-3-nitrochalcones as α -glucosidase and/or α -amylase inhibitors with potential anti-inflammatory activity. *Medicinal Chemistry Research*, 31(12), 2243-2259. <https://doi.org/10.1007/s00044-022-02980-1>
- [49] Sun, N., Gong, C., Zhou, Y., Zhang, Y., Zhang, N., Xing, L., & Xue, W. (2023). Design, synthesis, and bioactivity of chalcone derivatives containing indanone. *ACS omega*, 8(2), 2556-2563. <https://doi.org/10.1021/acsomega.2c07071>
- [50] Chen, S., Zhang, M., Feng, S., Gong, C., Zhou, Y., Xing, L., ... & Xue, W. (2023). Design, synthesis and biological activity of chalcone derivatives containing pyridazine. *Arabian Journal of Chemistry*, 16(7), 104852. <https://doi.org/10.1016/j.arabjc.2023.104852>
- [51] Koyiparambath, V. P., Oh, J. M., Khames, A., Abdelgawad, M. A., Nair, A. S., Nath, L. R., ... & Mathew, B. (2021). Trimethoxylated halogenated chalcones as dual inhibitors of MAO-B and BACE-1 for the treatment of neurodegenerative disorders. *Pharmaceutics*, 13(6), 850. <https://doi.org/10.3390/pharmaceutics13060850>
- [52] Gupta, D., & Jain, D. K. (2015). Chalcone derivatives as potential antifungal agents: Synthesis, and antifungal activity. *Journal of advanced pharmaceutical technology & research*, 6(3), 114-117. <https://doi.org/10.4103/2231-4040.161507>
- [53] Zhou, Q., Tang, X., Chen, S., Zhan, W., Hu, D., Zhou, R., ... & Xue, W. (2022). Design, synthesis, and antifungal activity of novel chalcone derivatives containing a piperazine fragment. *Journal of Agricultural and Food Chemistry*, 70(4), 1029-1036. <https://doi.org/10.1021/acs.jafc.1c05933>